These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 3918124)

  • 1. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF; Maslow MJ; Leibowitz RE; Pollock AA; Hanna BA; Schaefler S; Simberkoff MS; Rahal JJ
    J Infect Dis; 1985 Feb; 151(2):295-300. PubMed ID: 3918124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Amikacin resistance of clinical strains of Enterobacteriaceae and Pseudomonas].
    Moreva TV; Anisimova LA; Erova TE; Boronin AM
    Antibiot Khimioter; 1992 Apr; 37(4):25-8. PubMed ID: 1417311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term amikacin use. Effects on aminoglycoside susceptibility patterns of gram-negative bacilli.
    Moody MM; de Jongh CA; Schimpff SC; Tillman GL
    JAMA; 1982 Sep; 248(10):1199-202. PubMed ID: 6809965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
    Maslow MJ; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1985 Aug; 16(2):227-34. PubMed ID: 3934125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP; Louie TJ; O'Keefe P; Gorbach SL; Bartlett JG
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endemic resistance to amikacin among hospital isolates of gram-negative bacilli: implications for therapy.
    Wormser GP; Tatz J; Donath J
    Infect Control; 1983; 4(2):93-9. PubMed ID: 6404852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP; Louie TJ; Weinstein WM; Bartlett JG; Gorbach SL
    Ann Intern Med; 1975 Oct; 83(4):484-8. PubMed ID: 1101761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amikacin therapy for serious gram-negative infection.
    Pollock AA; Berger SA; Richmond AS; Simberkoff MS; Rahal JJ
    JAMA; 1977 Feb; 237(6):562-4. PubMed ID: 576282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of aminoglycoside--modifying enzymes in resistance of Gram-negative rods].
    Jakoniuk P; Wieczorek P; Sacha PT; Zalewska M; Leszczyńska K
    Med Dosw Mikrobiol; 2006; 58(4):363-70. PubMed ID: 17642314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.
    Gerding DN; Larson TA
    Am J Med; 1986 Jun; 80(6B):22-8. PubMed ID: 3089003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical monotherapy with meropenem or combination therapy: the microbiological point of view.
    Garcinuño P; Santibañez M; Gimeno L; Sánchez-Bautista A; Coy J; Sánchez-Paya J; Boix V; Merino E; Portilla J; Rodríguez JC
    Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1851-1855. PubMed ID: 27503076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns.
    Acar JF; Witchitz JL; Goldstein F; Talbot JN; Le Goffic F
    J Infect Dis; 1976 Nov; 134 SUPPL():S280-5. PubMed ID: 825587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Amikacin in a hospital for children: microbiological and clinical studies.
    Marget W; Reindke B; Versmold H
    J Infect Dis; 1976 Nov; 134 SUPPL():S412-9. PubMed ID: 825592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM; McGee ZA; Alford RH
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic resistance patterns during aminoglycoside restriction.
    Young EJ; Sewell CM; Koza MA; Clarridge JE
    Am J Med Sci; 1985 Dec; 290(6):223-7. PubMed ID: 3936358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of amikacin in treatment of infections due to gram-negative aerobic bacilli.
    Mathias RG; Ronald AR; Gurwith MJ; McCullough DW; Stiver HG; Berger J; Cates CY; Fox LM; Lank BA
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-401. PubMed ID: 825590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.